Management of the hemophilic patient poses unique challenges to the correctional health care system. Patients with severe disease require frequent intravenous infusions of factor to prevent bleeding episodes. New advances to prolong factor half-life have led to less frequent infusions and free up nursing resources. Newer therapy options can eliminate the need for intravenous infusions, while curative gene therapy is now available.

Educational Objectives

• Summarize basic concepts of factor replacement therapy
• Review new treatments such as gene therapy and bispecific antibodies
• List resources available to treatment of an incarcerated patient with hemophilia

Level:Intermediate